Government Rationalizes Trade Margins for 137 Anti-Cancer Drugs, Capping Them at 30 Percent of MRP
Distilled Policy Brief
- The National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals has rationalized the trade margins for 137 non-scheduled anti-cancer drugs, capping the trade margin at 30% of the Maximum Retail Price (MRP).
- The revised prices are expected to reduce MRPs by up to 70% based on existing price structures, taking effect from November 9, 2026, pursuant to Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013.
- This initiative expands upon NPPA's 2019 pilot exercise and is based on recommendations from a Directorate General of Health Services (DGHS) expert committee to alleviate the financial burden of cancer treatment on patients.
🎯 Prelims High-Yield Examination Points
The National Pharmaceutical Pricing Authority (NPPA) capped trade margins for 137 non-scheduled anti-cancer drugs at 30% of the MRP under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, with revised prices effective from November 9, 2026.
⚖️ Mains Analytical & Syllabus Linkages
Examine how trade margin rationalization (TMR) of essential medicines addresses out-of-pocket expenditure, ensures affordable healthcare access, and balances public health objectives with legitimate pharmaceutical manufacturing revenues in India.
🎯 UPSC Prelims Practice Drill
Consider the following statements regarding the rationalization of trade margins for anti-cancer drugs in India: 1. The National Pharmaceutical Pricing Authority (NPPA) has capped the trade margin at 30% of the Maximum Retail Price (MRP) for 137 non-scheduled anti-cancer drugs. 2. This measure has been enacted pursuant to Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013. 3. The revised prices under this notification become effective immediately upon publication without any transition period. Which of the statements given above are correct?
- [A] 1 and 2 only
- [B] 2 and 3 only
- [C] 1 and 3 only
- [D] 1, 2 and 3
▶ Reveal Official Answer & Analytical Explanation
Statements 1 and 2 are correct: The NPPA under the Department of Pharmaceuticals has rationalized trade margins for 137 non-scheduled anti-cancer drugs, capping them at 30% of the MRP pursuant to Paragraph 19 of the DPCO, 2013. Statement 3 is incorrect because the revised prices are scheduled to take effect from November 9, 2026, allowing a transition period for manufacturers and retailers to update their pricing and inventories.
🏛️ Historical Twin PYQ Anchor (2021)
Consider the following statements regarding the "National Clean Air Programme (NCAP)": 1. It is implemented by the Ministry of Environment, Forest and Climate Change. 2. Central Pollution Control Board acts as the sole regulatory executive body.